Breaking News, Collaborations & Alliances

GARDP, Bugworks Partner to Accelerate Novel Antibiotic

New broad-spectrum antibiotic compound aims to treat serious infections caused by multidrug-resistant bacteria.

The Global Antibiotic Research & Development Partnership (GARDP), joined forces with Bugworks Research Inc., a clinical-stage biopharmaceutical company, to accelerate the development of a new broad-spectrum antibiotic compound aimed at treating serious infections caused by multidrug-resistant bacteria. The compound being developed by Bugworks, BWC0977, aims to treat patients with serious bacterial infections in both critical care and community settings. BWC0977 has the potential to treat ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters